touchONCOLOGY were delighted to speak to Ross Camidge, University of Colorado Cancer Center, to discuss the recent FDA approved of brigatinib for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer.
Questions
1. What are the unmet needs in the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer? (0:06)
2. What clinical data led to the approval of brigatinib in this treatment setting? (0:46)
3. What safety issues should be considered when prescribing brigatinib? (2:00)
4. In which patients is brigatinib likely to be particularly beneficial and in whom is it contraindicated? (3:56)
5. What are the options for patients who develop resistance to brigatinib? (5:00)
Speaker disclosure: Ross Camidge has received honoraria and research funding from Takeda.
Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group.
